References
- Eriksson EA, Pellegrini DC, Vanderkolk WE, Minshall CT, Fakhry SM, Cohle SD. Incidence of pulmonary fat embolism at autopsy: an undiagnosed epidemic. J Trauma. 2011;71(2):312–315.
- McIff TE, Poisner AM, Herndon B, et al. Fat embolism: evolution of histopathological changes in the rat lung. J Orthop Res. 2010;28(2):191–197.
- McIff TE, Poisner AM, Herndon B, et al. Mitigating Effects of captopril and losartan on lung histopathology in a rat model of fat embolism. J Trauma. 2011;70(5):1186–1191.
- Fletcher A, Molteni A, Ponnapureddy R, Patel C, Pluym M, Poisner AM. The renin inhibitor aliskiren protects rat lungs from the histopathological effects of fat embolism. J Trauma Acute Care Surg. 2016;84:338–344.
- Poisner AM, Adler F, Uhal B, et al. Persistent and progressive pulmonary fibrotic changes in a model of fat embolism. J Trauma Acute Care Surg. 2012;72(4):992–998.
- Poisner AM, Herndon B, Lankachandra K, et al. Fat embolism sensitizes rats to a “second hit” with lipopolysaccharide: An animal model of pulmonary fibrosis. J Trauma Acute Care Surg. 2015;78(3):552–557.
- Ajemba O, Zia H, Lankachandra K, et al. Fat embolism syndrome following caesarean section in an obese patient and its histopathological similarity to an animal model of FE: a case report. Case Reports in Clinical Pathology 2015;2(3):30–35.
- Bruce E, Shenoy V, Rathinasabapathy A, et al. Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. Br J Pharmacol. 2015;172(9):2219–2231.
- Konigshoff M, Wilhelm A, Jahn A, et al. The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis. Am J Respir Cell Mol Biol. 2007;37(6):640–650.
- Rathinasabapathy A, Horowitz A, Kumar A, et al. C21, an AT2 receptor agonist, arrests the progression of bleomycin-induced pulmonary fibrosis and associated cardiac dysfunctions. Faseb J. 2016;(30 suppl):lb578.
- Meng Y, Li T, Zhou GS, et al. The angiotensin-converting enzyme 2/angiotensin (1-7)/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway. Antioxid Redox Signal. 2015;22(3):241–258.
- Ishii K, Takeuchi H, Fukunaga K, et al. Attenuation of lipopolysaccharide-induced acute lung injury after (pro)renin receptor blockade. Exp Lung Res. 2015;41(4):199–207.
- Chao J, Blanco G, Wood JG, Gonzalez NC. Renin released from mast cells activated by circulating MCP-1 initiates the microvascular phase of the systemic inflammation of alveolar hypoxia. Am J Physiol Heart Circ Physiol. 2011;301(6):H2264–H2270.
- Veerappan A, Reid AC, Estephan R, et al. Mast cell renin and a local renin-angiotensin system in the airway: Role in bronchoconstriction. Proc Natl Acad Sci USA. 2008;105(4):1315–1320.
- Veerappan A, O'Connor NJ, Brazin J, et al. Mast cells: a pivotal role in pulmonary fibrosis. DNA Cell Biol. 2013;32(4):206–218.
- Poisner AM, Hamidpour S, Ho A, et al. Losartan blocks the recruitment of mast cells in the lungs of rats subjected to fat embolism with or without a second hit with LPS. The FASEB Journal 2016;30(700):2.
- Poisner A, Herndon B, Al Hariri A, Qin C, Quinn T, Molteni A. Renin as a mediator of pulmonary damage caused by fat embolism and LPS. The FASEB Journal 2013;27(1 Supplement):lb444.